Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)
Rocket Pharmaceuticals (RCKT) posted Long-Term Investments of $34.3 million for Q4 2023, up 18.52% sequentially from $29.0 million in Q1 2023, and down 20.7% YoY from $43.3 million in Q4 2022.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023) Analysis & Trends
Rocket Pharmaceuticals has reported Long-Term Investments for 3 years, with the latest figure at $34.3 million in Q4 2023.
- Quarterly Long-Term Investments fell 20.7% year-over-year to $34.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $34.3 million (down 20.7% YoY) and the FY2023 annual result came in at $34.3 million, down 20.7% from the prior year.
- Long-Term Investments improved to $34.3 million in Q4 2023 per RCKT's latest filing, from $29.0 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $43.3 million in Q4 2022 and troughed at $29.0 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 34.32 Mn |
| Mar 31, 2023 | 28.96 Mn |
| Dec 31, 2022 | 43.28 Mn |
| Dec 31, 2018 | 7.40 Mn |
| Sep 30, 2018 | 32.00 Mn |
| Jun 30, 2018 | 39.36 Mn |